Management of comorbidities in older patients with cystic fibrosis. (Q38178773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Management of comorbidities in older patients with cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Scott Bell

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Barry J Plant

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

William D Plant

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

19 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

The Lancet. Respiratory medicine

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

164-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

Improved survival among young patients with cystic fibrosis

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Implementation of European standards of care for cystic fibrosis - provision of care

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Massive hemoptysis in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Pneumothorax in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Pulmonary exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Late diagnosis defines a unique population of long-term survivors of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Kinetics of Insulin Secretion and Glucose Intolerance in Adult Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cystic Fibrosis Related Diabetes (CFRD)—The End Stage of Progressive Insulin Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Mechanisms of glucose intolerance in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Hyperglycemia and death in cystic fibrosis-related diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Screening for cystic fibrosis-related diabetes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Microvascular complications in cystic fibrosis-related diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Prevalence of dyslipidemia in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cardiovascular injury and repair in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Increased augmentation index in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Incidence of deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Thrombolysis for indwelling catheter related thrombosis and superior vena cava obstruction in cystic fibrosis: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Survey of acute renal failure in patients with cystic fibrosis in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Case-control study of acute renal failure in patients with cystic fibrosis in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Hypochloremia and hyponatremia as the initial presentation of cystic fibrosis in three adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Renal impairment in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Peri-lung transplant renal issues in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Long‐term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Risk factors for chronic kidney disease in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Microalbuminuria in Patients With Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Case 5: assessment. Allergic tubular interstitial nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Renal histopathological lesions after lung transplantation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

A CF patient with progressive proteinuric renal disease: a CF-specific nodular glomerulosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Bone Mass and Vitamin D Deficiency in Adults with Advanced Cystic Fibrosis Lung Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Mechanisms of insulin resistance in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Guide to bone health and disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Beta-lactam allergy in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Nonimmediate β-lactam reactions in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Antibiotic desensitization in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Rapid desensitization for non-immediate reactions in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Predicting the future burden of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Digestive-tract cancer in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

The Risk of Cancer among Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cancer Risk in Nontransplanted and Transplanted Cystic Fibrosis Patients: A 10-Year Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Colon cancer in lung transplant recipients with CF: Increased risk and results of screening

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cancer risk among patients with cystic fibrosis and their first-degree relatives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Development of Low-Dose Protocols for Thin-Section CT Assessment of Cystic Fibrosis in Pediatric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Helicobacter pylori and Clostridium difficile in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Outcomes of lung transplantation for cystic fibrosis in a large UK cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Mechanisms of the rapid decline in glomerular filtration rate following lung transplantation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

The spectrum of mycobacterial infection after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970025-0

7 January 2021

10.1016/S2213-2600(13)70025-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429097%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference